Trials / Terminated
TerminatedNCT04542993
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
Can SARS-CoV-2 Viral Shedding in COVID-19 Disease be Reduced by Resveratrol-assisted Zinc Ingestion, a Direct Inhibitor of SARS-CoV-2-RNA Polymerase? A Single Blinded Phase II Protocol (Reszinate Trial)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Swedish Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Administration of Zinc and resveratrol or double placebo for a period of 5 days and will be monitored for a 14 day period in covid-19 positive patients in an outpatient setting
Detailed description
Research Question: In ambulatory, non-hospitalized patients with SARS-CoV-2 infection, is it possible to utilize resveratrol as a transporter for zinc treatment as means to minimize viral load and severity of resulting COVID-19 disease? 60 ambulatory SARS-CoV-2 positive volunteers who will be randomized into one of two treatment arms to receive either Zinc and resveratrol or double placebo for a period of 5 days and will be monitored for a 14 day period. It is anticipated to take approximately 20 weeks to accrue this cohort resulting in an estimated active project period of 22 weeks, although it may take up to 12 additional weeks to collect all of the data related to COVID-19 admissions in the cohort.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Zinc Picolinate | Zinc Picolinate (50 mg PO TID x 5 days) |
| DIETARY_SUPPLEMENT | Resveratrol | Resveratrol 2 grams po BID x 5 days |
| DIETARY_SUPPLEMENT | Zinc Picolinate Placebo | Zinc Picolinate Matched Placebo PO TID x 5 days |
| DIETARY_SUPPLEMENT | Resveratrol Placebo | Resveratrol Matched Placebo PO BID x 5 days |
Timeline
- Start date
- 2020-09-08
- Primary completion
- 2021-02-05
- Completion
- 2021-02-05
- First posted
- 2020-09-09
- Last updated
- 2022-07-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04542993. Inclusion in this directory is not an endorsement.